Cipla generates a significant portion of its global revenue from its world-renowned portfolio of respiratory medications, making advanced inhalers and combination therapies for asthma and chronic obstructive pulmonary disease among its most crucial commercial product lines. Medications incorporating active compounds like salmeterol, fluticasone, and formoterol lead its respiratory franchise, providing vital relief to millions of patients suffering from chronic respiratory conditions. Additionally, its extensive range of generic anti-infective formulations, cardiovascular treatments, and antiretroviral medications for HIV/AIDS management rank heavily among its highest-volume and most widely distributed pharmaceutical product offerings globally.